Open-label, Uncontrolled, Prospective Long-term Observation of Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years

Trial Profile

Open-label, Uncontrolled, Prospective Long-term Observation of Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Iloprost (Primary)
  • Indications Pulmonary arterial hypertension; Pulmonary hypertension
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms OPTION
  • Sponsors Bayer
  • Most Recent Events

    • 14 Aug 2017 Planned End Date changed from 12 Jun 2017 to 12 Sep 2017.
    • 14 Aug 2017 Planned primary completion date changed from 12 Jun 2017 to 12 Sep 2017.
    • 05 May 2017 Planned End Date changed from 1 Apr 2017 to 12 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top